StockAxis

Gland Pharma Ltd

Quarterly Result - Q2 FY23

Gland Pharma Ltd

Pharmaceuticals & Drugs

Current

CMP
Rs. 1698.95
Rating:
Hold
October 26, 2022

Previous

Rating:
Buy

Stock Info

BSE
543245
NSE
GLAND
Bloomberg
GLAND:IN
Reuters
GLAND:NS
Sector
Pharmaceuticals & Drugs
Face Value (Rs)
1
Equity Capital (Rs cr)
16
Mkt Cap (Rs cr)
27984.68
52w H/L (Rs)
4062.95 - 2031.00
Avg Daily Vol (BSE+NSE)
22,575

Shareholding Pattern

(as on 30-Aug)
%
Promoter
57.86
FIIs
6.10
DIIs
21.92
Public & Others
14.13
Source: Ace equity, StockAxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
7.77
-0.10
-40.27
Sensex
4.20
6.77
-2.33
Source: Ace equity, StockAxis Research

Indexed Stock Performance

Gland Pharma Ltd Sensex
Gland Pharma Ltd
Source: Ace equity, StockAxis Research

Financial Highlights:

Particulars (Rs. in Crores) Q2 FY23 Q1FY23 QOQ Q2 FY22 YOY
Revenue from Operations 1044.40 856.89 21.88% 1080.40 -3.33%
EBITDA 297.20 269.92 10.00% 376.70 -21.00%
PAT 241.70 229.17 5.00% 302.20 -20.00%
EPS 14.65 13.93 5.17% 18.37 -20.25%

Source: Company Filings; StockAxis Research

Q2 FY23 Highlights
Gland Pharma has posted good recovery across all parameters on QoQ basis. The revenue for the quarter stood at Rs 1044 cr as compared to Q1 FY23 at Rs 857 cr, an increase of 22%. EBITDA of the company stood at Rs 297 cr. during the quarter as compared to Rs 270 cr. in Q1 FY23, an increase of 10%. However, company’s EBITDA witnessed a downfall of 21% on YoY basis due to decline in top-line (on YoY basis) on account of price erosion, delay in supply of raw material, increased employee cost as company has added 400-500 employees during the quarter and increased freight cost. PAT for the quarter stood at Rs 242 cr. as compared to Q1 FY23 at Rs 229, an increase of 5%. The EPS of the company witnessed a growth of 5% and accounted for Rs 14.65.

Revenue breakup geography-wise

Particulars Q2 FY23 Q2 FY22 YoY Q1 FY23 QoQ
USA, Europe, Canada, and Australia (Core Markets) 747.5 722.5 3% 705.6 6%
India 72.6 125.8 -42% 51 -42%
ROW 224.3 232.2 -3% 100.2 12.40%
TOTAL 1044.4 1080.5 -3% 856.9 22%

Key Concall Highlights

  • During the quarter company launched 6 product SKUs. These are namely Bumetanide, Bortezomib and Oxaliplatin in USA, Europe and Canada respectively.
  • It is consistently looking for strong partnerships for its biologic/biosimilar CDMO space and is currently undergoing negotiations.
  • Company’s sales witnessed a significant decline on account of fall in sales of major products such as:
  • (a) Company’s commercial production of insulin restarted in the second half of the year, which has significantly impacted the sales for the Q2 FY23.
  • (b) Heparin on an average account for Rs 40-50cr per quarter. As per management the sales of Heparin hasn’t started yet, which has impacted overall sales for the Q2 FY23. Though, the management expects the sales to start again in November 22.
  • (c) The company has added three capacities of Lyophilizers which are running at 80% capacity utilisation levels.
  • As of September 30, 2022, the company has 322 ANDA filings in the United States, of which 259 were approved and 63 pending approvals.
  • It’s key markets USA, Canada, Europe and Australia have accounted for 72% of the total revenue in Q2 FY23 as compared to 67% in Q2FY22, followed by rest of the world sales at 21% and India sales at 7%.
  • The revenue from new launches during the quarter accounted for 3%.
  • Sales to US market is comprising of products sold to both US customers and Indian customers for US markets. For Q2FY23 direct sale to US customers ₹ 598 cr and to Indian customers for US markets was ₹ 75 cr, an aggregate of ₹ 674 cr. Total sales to US market grew by 5% & 6% on YoY basis & QoQ basis respectively.
  • The total ROW sales got affected on account of significant decline by 88% in sales in Canada, where Bortezomib (sold in Canada) declined by 65%. Overall sales in Canada accounted for 2% or ~ Rs 17 cr in Q2 FY23.
  • The company has incurred a Capex of Rs 83cr in H1-FY23 for increasing capacity at Pashamylaram and Vizag API facility. The company is expected to incur additional Rs 100 cr Capex by H2-FY23. For Q2-FY23 the total Capex amount is of Rs 41 cr i.e., 4% of revenue.
  • It has a cash & bank balance of Rs 3820 cr as on 30th September 2022 which will be used for funding Capex.
  • Company has opened new offices in USA and Singapore to strengthen its customer relations.

Outlook & valuation

Gland Pharma has witnessed an improved performance for the quarter ended 30th September 2022 although during Q2 FY23 company’s sales were impacted by delay in restarting the insulin supply, absence of sales of Heparin, disruption in bag manufacturing as well as some delay in Lyo installations and lower than expected revenue from its oncology segment. Going forward we expect improved margins on account of smooth flow of supply chain and decrease in prices of raw materials, along with easing US market conditions. It’s major products such as Heparin and insulin supply will come into force. The company has a robust business model with diversified product portfolio with many products in the USFDA shortages list. Overall we remain positive on the stock .

As per CMP of Rs 2225.3 (as on 26th October 2022), as per our estimates the stock is trading at 23.1x of its FY 25E earnings.

We recommend ‘HOLD’ to the stock.

Quarterly Financials

Particulars (Rs. in Crores) Q2 FY23 Q1FY23 QOQ Q2 FY22 YOY
Revenue from Operations 1044.40 856.90 21.88% 1080.40 -3.33%
COGS 519.30 374.05 524.00
Gross Profit 525.10 482.84 556.40
Gross Margin (%) 50.00% 56.35% 51.50%
Employee Benefit Expenses 101.20 98.00 82.30
Other Expenses 126.70 114.92 97.40
EBITDA 297.20 269.92 10.11% 376.70 -21.10%
EBITDA Margin (%) 28.00% 31.50% 34.87%
Depreciation 36.60 34.91 26.10
EBIT 260.60 235.01 10.89% 350.60 -25.67%
EBIT Margin (%) 25.00% 27.43% 32.45%
Finance Cost 1.70 0.90 1.00
Oher Income 65.60 74.39 51.10
Profit Before Exceptional Items & Tax 324.50 308.50 400.70
Exceptional Items - - -
Profit Before Tax 324.50 308.50 5.19% 400.70 -19.02%
Tax 82.80 79.33 98.50
Effective Tax Rate (%) 26.00% 25.71% 24.58%
Profit After Tax 241.70 229.17 5.47% 302.20 -20.02%
PAT Margin (%) 23.00% 26.74% 27.97%
Earnings Per Share (Rs.) 14.65 13.93 5.17% 18.37 -20.25%

Source: Company Filings; StockAxis Research

Consolidated Financial statements

Profit & Loss statement

Year End March (Rs. in Crores) 2021 2022 2023E 2024E 2025E
Net Sales 3462.90 4400.70 4050.00 4900.00 5900.00
Growth % 31.50% 27.10% -8.00% 21.00% 20.40%
Expenditure
Material Cost 1491.90 2109.30 1984.50 2303.00 2773.00
Employee Cost 311.40 338.60 401.00 416.50 501.50
Other Expenses 357.40 442.70 429.30 494.90 572.30
EBITDA 1302.30 1510.20 1235.30 1685.60 2053.20
Growth % 36.30% 16.00% -18.20% 36.50% 21.80%
EBITDA Margin 37.60% 34.30% 30.50% 34.40% 34.80%
Depreciation & Amortization 98.80 110.30 115.00 130.00 150.00
EBIT 1203.50 1399.90 1120.30 1555.60 1903.20
EBIT Margin % 34.80% 31.80% 27.70% 31.70% 32.30%
Other Income 134.80 223.90 181.20 221.00 222.00
Interest & Finance Charges 3.40 5.20 5.00 5.00 6.00
Profit Before Tax - Before Exceptional 1334.90 1618.50 1296.50 1771.60 2119.20
Profit Before Tax 1334.90 1618.50 1296.50 1771.60 2119.20
Tax Expense 337.80 406.90 326.30 445.90 534.00
Effective Tax rate 25.30% 25.10% 25.20% 25.20% 25.20%
Exceptional Items - - - - -
Net Profit 997.00 1211.60 970.10 1325.70 1585.20
Growth % 29.00% 21.50% -19.90% 36.70% 19.60%
Net Profit Margin 28.80% 27.50% 24.00% 27.10% 26.90%
Consolidated Net Profit 997.00 1211.60 970.10 1325.70 1585.20
Growth % 29.00% 21.50% -19.90% 36.70% 19.60%
Net Profit Margin after MI 28.80% 27.50% 24.00% 27.10% 26.90%

Balance Sheet

As of March (Rs. in Crores) 2021 2022 2023E 2024E 2025E
Share Capital 16.40 16.40 16.40 16.40 16.40
Total Reserves 5861.50 7141.20 8016.50 9298.40 9189.50
Shareholders' Funds 5903.30 7157.60 8032.90 9314.80 9205.90
Minority Interest - - - - -
Non Current Liabilities
Long Term Burrowing 3.90 4.50 2.10 3.10 3.10
Deferred Tax Assets / Liabilities 73.90 87.80 87.80 87.80 87.80
Long Term Provisions - - - - -
Current Liabilities
Short Term Borrowings - 0.30 - - -
Trade Payables 400.70 462.90 474.60 514.90 562.20
Other Current Liabilities 58.00 76.20 76.20 76.20 76.20
Short Term Provisions 53.80 42.80 42.80 42.80 42.80
Total Equity & Liabilities 6496.10 7833.90 8718.00 10042.00 10179.60
Assets
Net Block 954.20 1701.90 1886.90 2106.90 2406.90
Non Current Investments 0.50 0.50 0.50 0.50 0.50
Long Term Loans & Advances 78.00 83.60 83.60 83.60 83.60
Current Assets
Currents Investments - 154.90 200.00 200.00 200.00
Inventories 1275.20 1185.70 1389.20 1287.30 1553.40
Sundry Debtors 671.00 1198.80 1134.50 1103.40 1213.20
Cash and Bank 3005.20 3093.40 3607.60 3114.40 2958.30
Short Term Loans and Advances 87.60 0.50 0.50 0.50 0.50
Total Assets 6496.10 7833.90 8718.07 10042.00 10179.40

Cash Flow Statement

Year End March (Rs. in Crores) 2021 2022 2023E 2024E 2025E
Profit After Tax 1334.90 1618.50 970.10 1325.70 1585.20
Depreciation 98.80 110.30 115.00 130.00 150.00
Others 0.70 38.00 - -
Changes in Working Capital -435.80 -338.10 -127.40 173.20 -327.60
Cash From Operating Activities 604.90 790.70 707.70 1028.90 1107.60
Purchase of Fixed Assets -228.80 -511.00 -300.00 -350.00 -450.00
Free Cash Flows 376.20 279.70 407.70 678.90 657.60
Others -1296.20 -492.00 - - -
Cash Flow from Investing Activities -1524.50 -1002.60 -300.00 -350.00 -450.00
Increase / (Decrease) in Loan Funds -0.90 -1.00 -1.00 1.00 -1.00
Equity Dividend Paid - - - -
Others 1239.40 34.90 - -
Cash from Financing Activities 1238.50 33.90 -1.00 1.00 -1.00
Net Cash Inflow / Outflow 318.80 -178.00 406.70 679.90 656.60
Opening Cash & Cash Equivalents 169.50 488.30 310.40 717.10 1397.00
Closing Cash & Cash Equivalent 488.30 310.40 717.10 1397.00 2053.60

Key Ratios

Year End March 2021 2022 2023E 2024E 2025E
Basic EPS 60.70 73.70 59.00 80.70 96.50
Diluted EPS 60.70 73.70 59.00 80.70 96.50
Cash EPS (Rs) 66.70 80.50 66.00 88.60 105.60
DPS - - - -
Book value (Rs/share) 359.30 435.70 488.90 566.90 560.30
ROCE (%) Post Tax 20.90% 18.60% 12.80% 15.30% 17.20%
ROE (%) 16.90% 16.90% 12.10% 14.20% 17.20%
Inventory Days 107.10 102.00 116.00 100.00 88.00
Receivable Days 67.10 78.00 105.00 83.00 72.00
Payable Days 34.20 36.00 42.00 37.00 33.00
PE 40.70 33.50 37.70 27.60 23.10
P/BV 6.90 5.70 4.60 3.90 4.00
EV/EBITDA 29.00 24.80 29.00 19.70 16.30
Dividend Yield (%) 0.00% 0.00% 0.00% 0.00% 0.00%
P/Sales 11.80 9.20 9.00 7.50 6.20
Net debt/Equity - - - - -
Net Debt/ EBITDA -2.30 -2.10 -0.60 -2.00 0.00
Sales/Net FA (x) 3.60 3.30 2.30 2.50 2.60